Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC
Kate Dixon(University of Minnesota), Bruce Walcheck(University of Veterinary Science), Ryan Bjordahl(Fate Therapeutics (United States)), Jeffrey S. Miller(Science Museum of Minnesota), Jianming Wu(Guangxi Academy of Agricultural Science), Ramzey Abujarour(Fate Therapeutics (United States)), Jason Dinella(Fate Therapeutics (United States)), Paul Rogers(Fate Therapeutics (United States)), Zachary Davis(University of Minnesota), Bahram Valamehr(Fate Therapeutics (United States)), Melissa Khaw(University of Minnesota), Kristin M. Snyder(University of Minnesota), Robert Hullsiek(University of Minnesota), Tom Lee(Fate Therapeutics (United States)), Hui-Yi Chu(Fate Therapeutics (United States))
Cited by 8
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195